Have you heard of the recently discovered 8th human-infecting #coronavirus designated CCoV-HuPn-2018?
We reveal the architecture of its spike (ie infection machinery), receptor usage and antigenic properties!

Led by @aletortorici

1/12

biorxiv.org/content/10.110…
CCoV-HuPn-2018 is a canine-feline recombinant alpha-#coronavirus isolated from the respiratory swab of a child hospitalized with pneumonia, indicating that more coronaviruses are spilling over to humans than previously appreciated.

2/12

academic.oup.com/cid/advance-ar…
We determined #cryoEM structures of the CCoV-HuPn-2018 spike in two markedly different conformational states which we propose to correspond to two snapshots of viral entry.

3/12
The CCoV-HuPn-2018 spike harbors a domain 0 upstream from the 'canonical NTD' (aka domain A) and they share the same fold (despite <13% aa sequence identity). Domain 0 interacts with host carbohydrates for some alphacoronaviruses and perhaps CCoV-HuPn-2018 does too.

4/12
Based on structural similarity with PRCV/TGEV, we postulated that the CCoV-HuPn-2018 spike receptor-binding domain (RBD, domain B) could bind APN which is an entry receptor for some alphacoronaviruses, including PRCV/TGEV.

5/12
The CCoV-HuPn-2018 spike receptor-binding domain (RBD, domain B) binds to feline, canine & porcine APN orthologs but not human APN (similar to PRCV/TGEV), which is surprising as CCoV-HuPn-2018 was isolated from an hospitalized child.

6/12
It turns out that one of the differences between human APN and feline, canine & porcine APNs is a Thr to Arg residue substitution at position 741, in the receptor region recognized by PRCV/TGEV.

7/12
Previous work showed that abrogation of this glycosylation site prevented binding of the TGEV RBD to cell-surface expressed porcine APN and we wondered if it could be the case for CCoV-HuPn-2018 as well.

8/12

journals.plos.org/plospathogens/…
Feline, canine & porcine APNs, and human R741T APN (N739 oligosaccharide knockin mutant) render cells permissive to CCoV-HuPn-2018 spike-mediated entry and soluble APNs inhibit this in a concentration-dependent manner. Thus APN is an entry receptor for CCoV-HuPn-2018!

9/12
APN single nucleotide polymorphisms have been described in humans, including at R741 (wo introducing a glycan) and we think that such variations might be present in infected individuals.
Please get in touch if interested in helping us find out.

10/12

sciencedirect.com/science/articl…
Polyclonal plasma neutralizing antibodies elicited by 'common cold' 229E infection also cross-neutralized (to various extent) CCoV-HuPn-2018 spike-mediated entry, which has the potential to reduce disease severity of this virus in humans.

11/12
This work would not have been possible without @coronalexington Anshu Joshi @YoungjunPark11 and our fantastic collaborators @atelentia @LanzavecchiaB @DavideCorti6 @jbloom_lab and many others not on twitter

12/12

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with The Veesler Lab

The Veesler Lab Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @veeslerlab

11 Aug
Sharing our latest preprint on #SARSCoV2 B.1.617.2 (delta), B.1.617.2+ (delta+) and B.1.617.1 (kappa) variants led by @Dr_MattMcCallum

1/9

biorxiv.org/content/10.110…
We show that vaccine-elicited neutralizing activity is reduced against delta and kappa and even more against delta+ relative to the vaccine-matched pseudovirus. Delta+ reduces neutralization ~ to B.1.351 (beta) which has the greatest magnitude of immune evasion thus far.

2/9
Half of the J&J-vaccinated individuals in our panel had no residual variant neutralization. Although we only analyzed neutralizing antibodies (T cells are also key players for in vivo protection), this supports offering second vaccine dose

3/9

abc7news.com/coronavirus-sf…
Read 9 tweets
1 Apr
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant is skyrocketing in California. We describe how it evades the host immune response with @DavideCorti6 @LucaPiccoli9

Led by @Dr_MattMcCallum, Jessica Bassi, Anna De Marco, Alex Chen & @coronalexington

1/7

biorxiv.org/content/10.110…
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant comprises 3 spike mutations: S13I, W152C & L452R reducing plasma neutralizing activity by ~3x and ~5x for vaccine- and infection-elicited antibodies (Abs), compared to the 'ancestral' virus.

2/7
The neutralization potency of 1/3 of RBD Abs is reduced or abrogated by the L452R spike mutation present in #SARSCoV2 CAL20.C (B.1.427/B.1.429), including clinical-stage antibodies such as Eli Lilly LY-CoV555 (bamlanivimab) & Celltrion CT-P59 (regdanvimab)

3/7
Read 7 tweets
14 Jan
We report an analysis of #SARSCoV2 spike NTD antigenic sites targeted by monoclonal antibodies (mAbs) in #COVID19 patients in collaboration with @DavideCorti6 and Matteo Samuele Pizzuto @Vir_Biotech

Work led by @Dr_MattMcCallum & Anna De Marco

1/10

biorxiv.org/content/10.110…
We found that NTD-specific mAbs account for 6-20% of mAbs cloned from memory B cells in #COVID19 patients and that the most potent of them neutralize #SARSCoV2 as efficiently as ultrapotent RBD-specific mAbs and trigger Fc-mediated effector functions effectively.

2/10
We delineated an antigenic map of the #SARSCoV2 spike NTD using #cryoEM (including a 2.2Å structure) and binding assays revealing the presence of a site of vulnerability recognized by all potently neutralizing mAbs described thus far.

3/10
Read 10 tweets
30 Dec 20
We discovered a neutralizing mouse monoclonal antibody (B6) targeting the coronavirus spike fusion machinery (S2 subunit) in collaboration with @McGuire_Lab

Work led by @MaxMSauer

biorxiv.org/content/10.110…

1/6
We identified by cryoEM that B6 recognizes the spike stem helix and cross-reacts with at least 8 distinct coronavirus spikes including those of the three highly pathogenic (#SARSCoV2, SARS-CoV and MERS-CoV) and the two endemic (OC43 and HKU1) human β-coronaviruses.

2/6
B6 broadly neutralizes spike-mediated entry into cells of distantly related coronaviruses including OC43 (lineage A) as well as MERS-CoV and HKU4 (lineage C) with comparable potencies.

3/6
Read 6 tweets
30 Oct 20
The peer-reviewed version of our article describing the design and evaluation of a multivalent #SARSCoV2 receptor-binding domain #COVID19 vaccine is out!

Work Led by @coronalexington and Brooke Fiala.

cell.com/cell/fulltext/…

1/6
Based on our previous studies of the immune response to coronavirus infections, we identified that the receptor-binding domain is immunodominant and accounts for most of the neutralizing activity in convalescent plasma/sera.

cell.com/cell/fulltext/…

2/6
We therefore reached out to @KingLabIPD who had recently developed a self-assembling two component protein nanoparticle platform allowing to multivalently display respiratory syncytial virus F that elicit high-titers of neutralizing antibodies.

cell.com/cell/fulltext/…

3/6
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(